GLUE — Monte Rosa Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $305.70m
- -$66.45m
- $75.62m
- 36
- 40
- 36
- 30
Annual cashflow statement for Monte Rosa Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -35.9 | -74 | -109 | -135 | -72.7 |
| Depreciation | |||||
| Non-Cash Items | 8.03 | 6.18 | 14.4 | 12.9 | 15.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.25 | 6.29 | -2.13 | 72.5 | 91.4 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -23.1 | -59.4 | -92.5 | -43.8 | 42 |
| Capital Expenditures | -3.39 | -9.73 | -12.9 | -19 | -3.99 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | 0.079 | -206 | 108 | -40.5 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -3.39 | -9.65 | -219 | 88.8 | -44.5 |
| Financing Cash Flow Items | -0.44 | -3.34 | -0.364 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 60.1 | 378 | 20.5 | 27.5 | 98.9 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 33.6 | 309 | -291 | 72.5 | 96.4 |